ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand
After a $625 million IPO, the biggest ever in biotech, obesity-focused Kailera Therapeutics is readying a commercial strategy that puts patients at the center.
ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand Read More »
